Momentum Biotechnologies
Can Ozbal is the Founder and CEO of Momentum Biotechnologies, a specialized CRO providing mass spectrometry-based native detection technologies to biopharmaceutical clients globally. Previously, Can served as Director of RapidFire Operations at Agilent Technologies, Chief Operating Officer at BIOCIUS Life Sciences, Inc., and Vice President and General Manager of RapidFire Products at BioTrove, Inc. Can also has experience as an Instructor at the Massachusetts Institute of Technology. Can holds a Ph.D. in Toxicology from MIT.
Momentum Biotechnologies
Momentum Biotechnologies is a drug discovery partner that delivers innovative mass spec solutions to overcome research challenges for biopharma clients globally. Our core team of scientists and engineers started working together developing the RapidFire high-throughput MS platform and have been serving clients with MS-based services since 2004 including PureHoney Technologies (2015-23). Momentum Biotechnologies’ goal is to accelerate our partners’ drug discovery & development programs through superior mass spec based CRO services. We help clients identify and characterize leads for degraders, molecular glues, protein-protein interaction (PPI) disrupters, RNA binders and other target classes. We use innovative techniques including affinity selection MS (ASMS), intact mass MS, chemoproteomics and small & biomolecule analyses. We pride ourselves on rapid turnaround of the highest quality data, accelerating the momentum of our clients’ research projects. We have a large Mass Spec lab with 30+ instruments and a fully functional BL2 lab in Billerica, Massachusetts. For more information, please visit www.momentum.bio.